{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:51:16Z","timestamp":1791143476655,"version":"4.1.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.autrev.2014.01.056","type":"journal-article","created":{"date-parts":[[2014,1,26]],"date-time":"2014-01-26T09:49:20Z","timestamp":1390729760000},"page":"762-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Biotherapies in Beh\u00e7et's disease"],"prefix":"10.1016","volume":"13","author":[{"given":"Clo\u00e9","family":"Comarmond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.autrev.2014.01.056_bb0005","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et's disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med"},{"issue":"8697","key":"10.1016\/j.autrev.2014.01.056_bb0010","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease. International Study Group for Beh\u00e7et's Disease","volume":"335","year":"1990","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.056_bb0020","article-title":"The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","author":"Davatchi","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/08830189709116843","article-title":"Pathogenic gene responsible for the predisposition of Beh\u00e7et's disease","volume":"14","author":"Mizuki","year":"1997","journal-title":"Int Rev Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2014.01.056_bb0030","first-page":"259","article-title":"The high prevalence of HLA-B5 in Beh\u00e7et's disease","volume":"30","author":"Yazici","year":"1977","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2014.01.056_bb0035","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/art.24642","article-title":"HLA-B51\/B5 and the risk of Beh\u00e7et's disease: a systematic review and meta-analysis of case\u2013control genetic association studies","volume":"61","author":"De Menthon","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2014.01.056_bb0040","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1755-3768.1992.tb04888.x","article-title":"The association between HLA B5 and ocular involvement in Beh\u00e7et's disease in southern Turkey","volume":"70","author":"Soylu","year":"1992","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2014.01.056_bb0045","first-page":"S53","article-title":"The lumps and bumps of Beh\u00e7et's syndrome","volume":"3","author":"Yazici","year":"2004","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0050","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.autrev.2012.11.001","article-title":"Association of allelic variants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase with thrombosis or ocular involvement in Beh\u00e7et's disease: a systematic review and meta-analysis","volume":"12","author":"Chamorro","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2014.01.056_bb0055","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.27568","article-title":"Mortality in Beh\u00e7et's disease","volume":"62","author":"Saadoun","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2014.01.056_bb0060","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2014.01.056_bb0065","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","article-title":"Management of Beh\u00e7et disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Beh\u00e7et disease","volume":"68","author":"Hatemi","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2014.01.056_bb0070","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/imt.13.66","article-title":"Approaches to immunosuppression in Beh\u00e7et's disease","volume":"5","author":"Comarmond","year":"2013","journal-title":"Immunotherapy"},{"issue":"12","key":"10.1016\/j.autrev.2014.01.056_bb0075","first-page":"2301","article-title":"Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Beh\u00e7et's disease","volume":"21","author":"Hamzaoui","year":"1994","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1601-0825.2005.01185.x","article-title":"Diversity of gammadelta T cells in patients with Beh\u00e7et's disease is indicative of polyclonal activation","volume":"12","author":"Freysdottir","year":"2006","journal-title":"Oral Dis"},{"issue":"4 Suppl. 50","key":"10.1016\/j.autrev.2014.01.056_bb0085","first-page":"S59","article-title":"Preferential activation of circulating CD8+ and gammadelta T cells in patients with active Beh\u00e7et's disease and HLA-B51","volume":"26","author":"Yasuoka","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2014.01.056_bb0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.autrev.2006.08.008","article-title":"Increased proportion of CD3+CD4\u2212CD8\u2212 double-negative T cells in peripheral blood of children with Beh\u00e7et's disease","volume":"6","author":"Ling","year":"2007","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0095","doi-asserted-by":"crossref","first-page":"R262","DOI":"10.1186\/ar785","article-title":"Vgamma9\/Vdelta2 T lymphocytes in Italian patients with Beh\u00e7et's disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease","volume":"5","author":"Triolo","year":"2003","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0100","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar3043","article-title":"Phenotype and functional changes of Vgamma9\/Vdelta2 T lymphocytes in Beh\u00e7et's disease and the effect of infliximab on Vgamma9\/Vdelta2 T cell expansion, activation and cytotoxicity","volume":"12","author":"Accardo-Palumbo","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cyto.2008.10.007","article-title":"Interleukin-6 in neuro-Beh\u00e7et's disease: association with disease subsets and long-term outcome","volume":"44","author":"Akman-Demir","year":"2008","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.autrev.2014.01.056_bb0110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.clineuro.2009.02.001","article-title":"CSF levels of cytokines in neuro-Beh\u00e7et's disease","volume":"111","author":"Borhani Haghighi","year":"2009","journal-title":"Clin Neurol Neurosurg"},{"issue":"8","key":"10.1016\/j.autrev.2014.01.056_bb0115","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-4632.2004.02184.x","article-title":"Serum interleukin-8 as a serologic marker of activity in Beh\u00e7et's disease","volume":"44","author":"G\u00fcr-Toy","year":"2005","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-4632.2009.03905.x","article-title":"Significance of serum interleukin-8 levels in patients with Beh\u00e7et's disease: high levels may indicate vascular involvement","volume":"48","author":"Durmazlar","year":"2009","journal-title":"Int J Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2014.01.056_bb0125","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/art.20334","article-title":"Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Beh\u00e7et's disease","volume":"50","author":"Ben Ahmed","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3129\/i07-179","article-title":"Th1 polarization of the immune response in uveitis in Beh\u00e7et's disease","volume":"43","author":"Ilhan","year":"2008","journal-title":"Can J Ophthalmol"},{"issue":"4 Suppl. 60","key":"10.1016\/j.autrev.2014.01.056_bb0135","first-page":"S27","article-title":"A Th1 but not a Th17 response is present in the gastrointestinal involvement of Beh\u00e7et's disease","volume":"28","author":"Ferrante","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0140","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaut.2004.07.005","article-title":"Abnormal expression of chemokine receptors in Beh\u00e7et's disease: relationship to intracellular Th1\/Th2 cytokines and to clinical manifestations","volume":"23","author":"Houman","year":"2004","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.autrev.2014.01.056_bb0145","doi-asserted-by":"crossref","first-page":"CR227","DOI":"10.12659\/MSM.881720","article-title":"Expression of Th-17 and ROR\u03b3t mRNA in Beh\u00e7et's disease","volume":"17","author":"Hamzaoui","year":"2011","journal-title":"Med Sci Monit"},{"issue":"4 Suppl. 60","key":"10.1016\/j.autrev.2014.01.056_bb0150","first-page":"S16","article-title":"Imbalance of Th17 to Th1 cells in Beh\u00e7et's disease","volume":"28","author":"Kim","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2014.01.056_bb0155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jneuroim.2011.01.012","article-title":"RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Beh\u00e7et's disease","volume":"233","author":"Hamzaoui","year":"2011","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0160","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","article-title":"Critical role of IL-21 in modulating TH17 and regulatory T cells in Beh\u00e7et disease","volume":"128","author":"Geri","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2014.01.056_bb0165","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/rheumatology\/keq330","article-title":"IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Beh\u00e7et's disease","volume":"50","author":"Liu","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2014.01.056_bb0170","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.autrev.2011.12.005","article-title":"Cytokines and Beh\u00e7et's disease","volume":"11","author":"Zhou","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2014.01.056_bb0175","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.autrev.2009.10.005","article-title":"Etiopathogenesis of Beh\u00e7et's disease","volume":"9","author":"Mendoza-Pinto","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2014.01.056_bb0180","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","article-title":"New insights into the pathogenesis of Beh\u00e7et's disease","volume":"11","author":"Pineton de Chambrun","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2014.01.056_bb0185","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00407749","article-title":"Beh\u00e7et's syndrome: treatment with recombinant leukocyte alpha-interferon","volume":"278","author":"Tsambaos","year":"1986","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.autrev.2014.01.056_bb0190","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000246374","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et's disease","volume":"192","author":"Azizlerli","year":"1996","journal-title":"Dermatology (Basel)"},{"issue":"6","key":"10.1016\/j.autrev.2014.01.056_bb0200","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","article-title":"Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Beh\u00e7et disease","volume":"146","author":"Gueudry","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0205","first-page":"896","article-title":"Longterm visual prognosis of patients with ocular Adamantiades\u2013Beh\u00e7et's disease treated with interferon-alpha-2a","volume":"35","author":"Krause","year":"2008","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0210","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Beh\u00e7et disease: review of the literature","volume":"33","author":"K\u00f6tter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2014.01.056_bb0215","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et's disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0220","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"issue":"13","key":"10.1016\/j.autrev.2014.01.056_bb0225","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0755-4982(05)84079-5","article-title":"Infliximab in the treatment of posterior uveitis in Beh\u00e7et's disease. Long term follow up in four patients","volume":"34","author":"Lanthier","year":"2005","journal-title":"Presse Med"},{"issue":"6","key":"10.1016\/j.autrev.2014.01.056_bb0230","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/ard.2004.025882","article-title":"Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors","volume":"64","author":"Bodaghi","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0235","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-009-1213-z","article-title":"One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh\u00e7et's disease refractory to standard immunosuppressive drugs","volume":"31","author":"Giardina","year":"2011","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0240","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et's disease","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn J Ophthalmol"},{"issue":"18","key":"10.1016\/j.autrev.2014.01.056_bb0245","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.3748\/wjg.14.2912","article-title":"Cytomegalovirus colitis in a patient with Beh\u00e7et's disease receiving tumor necrosis factor alpha inhibitory treatment","volume":"14","author":"Sari","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"8","key":"10.1016\/j.autrev.2014.01.056_bb0250","doi-asserted-by":"crossref","first-page":"1034, 1148","DOI":"10.1136\/bjo.2007.127522","article-title":"Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha","volume":"92","author":"Evereklioglu","year":"2008","journal-title":"Br J Ophthalmol."},{"issue":"10","key":"10.1016\/j.autrev.2014.01.056_bb0255","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1469-0691.2007.01796.x","article-title":"Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment","volume":"13","author":"Mancini","year":"2007","journal-title":"Clin Microbiol Infect"},{"issue":"11 Suppl.","key":"10.1016\/j.autrev.2014.01.056_bb0260","first-page":"928","article-title":"Interferon alfa combined with azathioprine for the uveitis of Beh\u00e7et's disease: an open study","volume":"4","author":"Hamuryudan","year":"2002","journal-title":"Isr Med Assoc J"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0265","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","article-title":"Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Beh\u00e7et disease: results of an open 4-center trial","volume":"33","author":"K\u00f6tter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2014.01.056_bb0270","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/rheumatology\/ken172","article-title":"Interferon-alpha\u2014a new therapeutic option in refractory juvenile Beh\u00e7et's disease with CNS involvement","volume":"47","author":"Kuemmerle-Deschner","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0275","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1381612053382179","article-title":"Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation","volume":"11","author":"Yasui","year":"2005","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10.1016\/j.autrev.2014.01.056_bb0280","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0285","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MD.0b013e3181dfca14","article-title":"Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis","volume":"89","author":"Hello","year":"2010","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.autrev.2014.01.056_bb0290","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Beh\u00e7et's disease","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0295","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10067-009-1272-2","article-title":"Adalimumab treatment for life threatening pulmonary artery aneurysm in Beh\u00e7et disease: a case report","volume":"29","author":"Lee","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0300","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et's disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2014.01.056_bb0305","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/ibd.20869","article-title":"Intestinal Beh\u00e7et's disease: maintenance of remission with adalimumab monotherapy","volume":"15","author":"Ariyachaipanich","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.autrev.2014.01.056_bb0310","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Md","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0315","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.056_bb0320","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","article-title":"Anti-TNF-alpha therapy in seven patients with Beh\u00e7et's uveitis: advantages and controversial aspects","volume":"1110","author":"Tognon","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0325","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh\u00e7et disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.autrev.2014.01.056_bb0330","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2014.01.056_bb0335","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et's disease: an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0340","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/bjophthalmol-2012-302515","article-title":"Health- and vision-related quality of life in patients receiving infliximab therapy for Beh\u00e7et uveitis","volume":"97","author":"Sakai","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.autrev.2014.01.056_bb0345","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease","volume":"14","author":"Tabbara","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0350","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades\u2013Beh\u00e7et disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.autrev.2014.01.056_bb0355","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2013.02.002","article-title":"Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies","volume":"12","author":"Saadoun","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0360","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","article-title":"Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et's disease","volume":"26","author":"Abu El-Asrar","year":"2005","journal-title":"Int Ophthalmol"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0365","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/112067210401400515","article-title":"Infliximab for the treatment of posterior uveitis with retinal neovascularization in Beh\u00e7et disease","volume":"14","author":"Giansanti","year":"2004","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"10.1016\/j.autrev.2014.01.056_bb0370","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kep126","article-title":"Effects of anti-TNF-alpha antibody infliximab in refractory entero-Beh\u00e7et's disease","volume":"48","author":"Iwata","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"9278","key":"10.1016\/j.autrev.2014.01.056_bb0375","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et's disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.autrev.2014.01.056_bb0380","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et's disease: a 24-month follow-up study","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0385","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","article-title":"Safety and efficacy of infliximab therapy in active Beh\u00e7et's uveitis: an open-label trial","volume":"29","author":"Al-Rayes","year":"2008","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0390","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","article-title":"Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease","volume":"130","author":"Okada","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"3 Suppl. 72","key":"10.1016\/j.autrev.2014.01.056_bb0395","first-page":"S62","article-title":"Switching of anti-TNF-\u03b1 agents in Beh\u00e7et's disease","volume":"30","author":"Furuta","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2014.01.056_bb0400","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","article-title":"Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis","volume":"31","author":"Takase","year":"2011","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0405","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1157\/13083329","article-title":"Medium-long term treatment with infliximab and methotrexate in posterior and\/or chronic uveitis refractory to conventional treatment","volume":"126","author":"Cobo-Ib\u00e1\u00f1ez","year":"2006","journal-title":"Med Clin (Barc)"},{"issue":"10","key":"10.1016\/j.autrev.2014.01.056_bb0410","first-page":"1428","article-title":"Production of TNF-alpha and IL-1 in active Beh\u00e7et's disease","volume":"17","author":"Hamzaoui","year":"1990","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2014.01.056_bb0415","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","article-title":"Resistant Beh\u00e7et disease responsive to Anakinra","volume":"149","author":"Botsios","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.autrev.2014.01.056_bb0420","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Beh\u00e7et's disease: an open-label pilot study","volume":"71","author":"G\u00fcl","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2014.01.056_bb0425","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","article-title":"Canakinumab in a patient with juvenile Beh\u00e7et's syndrome with refractory eye disease","volume":"71","author":"Ugurlu","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3 Suppl. 72","key":"10.1016\/j.autrev.2014.01.056_bb0430","first-page":"S115","article-title":"Successful use of canakinumab in a patient with resistant Beh\u00e7et's disease","volume":"30","author":"Cantarini","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2014.01.056_bb0435","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/030097402320318387","article-title":"Cytokine profile in Beh\u00e7et's disease patients. Relationship with disease activity","volume":"31","author":"Hamzaoui","year":"2002","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0440","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","article-title":"Tocilizumab treatment for neuro-Beh\u00e7et's disease, the first report","volume":"114","author":"Shapiro","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"issue":"3 Suppl. 72","key":"10.1016\/j.autrev.2014.01.056_bb0445","first-page":"S73","article-title":"Refractory neuro-Beh\u00e7et treated by tocilizumab: a case report","volume":"30","author":"Urbaniak","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2014.01.056_bb0450","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","article-title":"A case of Beh\u00e7et's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"22","author":"Hirano","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0455","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Beh\u00e7et's disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0460","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-008-0057-9","article-title":"Treatment of retinal vasculitis in Beh\u00e7et's disease with rituximab","volume":"18","author":"Sadreddini","year":"2008","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2014.01.056_bb0465","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/RHU.0b013e318284735c","article-title":"Remission induction in a case of refractory Beh\u00e7et disease with Alemtuzumab","volume":"19","author":"Perez-Pampin","year":"2013","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2014.01.056_bb0470","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Beh\u00e7et's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2014.01.056_bb0475","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et's disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.autrev.2014.01.056_bb0480","first-page":"1098","article-title":"Systemic interferon alpha 2b treatment in Beh\u00e7et's syndrome","volume":"21","author":"Hamuryudan","year":"1994","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2014.01.056_bb0485","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","article-title":"Safety and effectiveness of interferon alpha-2a in treatment of patients with Beh\u00e7et's uveitis refractory to conventional treatments","volume":"117","author":"Sobaci","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.autrev.2014.01.056_bb0490","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10384-012-0182-z","article-title":"Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy","volume":"56","author":"Yoshida","year":"2012","journal-title":"Jpn J Ophthalmol"},{"issue":"9","key":"10.1016\/j.autrev.2014.01.056_bb0495","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/bjo.2010.194464","article-title":"Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Beh\u00e7et's disease on infliximab therapy","volume":"95","author":"Keino","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0500","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3109\/s10165-011-0585-6","article-title":"Good response to infliximab in a patient with deep vein thrombosis associated with Beh\u00e7et disease","volume":"22","author":"Yoshida","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2014.01.056_bb0505","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10067-011-1726-1","article-title":"Infliximab for patients with neuro-Beh\u00e7et's disease: case series and literature review","volume":"30","author":"Borhani Haghighi","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0510","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/ard.62.3.280","article-title":"Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Beh\u00e7et's syndrome","volume":"62","author":"Licata","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2014.01.056_bb0515","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/jnnp.2004.055434","article-title":"Efficacy of TNF alpha blockade in cyclophosphamide resistant neuro-Beh\u00e7et disease","volume":"76","author":"Ribi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0520","first-page":"181","article-title":"Successful treatment of long-standing neuro-Beh\u00e7et's disease with infliximab","volume":"32","author":"Sarwar","year":"2005","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0525","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.2006.056804","article-title":"Successful treatment of refractory neuro-Beh\u00e7et's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile","volume":"66","author":"Fujikawa","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2014.01.056_bb0530","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","article-title":"Effect of infliximab in progressive neuro-Beh\u00e7et's syndrome","volume":"272","author":"Kikuchi","year":"2008","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2014.01.056_bb0535","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","article-title":"Infliximab for the treatment of Neuro-Beh\u00e7et's disease: a case series and review of the literature","volume":"59","author":"Pipitone","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2014.01.056_bb0540","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.2006.064279","article-title":"Adalimumab: a new modality for Beh\u00e7et's disease?","volume":"66","author":"Van Laar","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl. 50","key":"10.1016\/j.autrev.2014.01.056_bb0545","first-page":"S133","article-title":"Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Beh\u00e7et's disease","volume":"26","author":"Belzunegui","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0560","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clineuro.2006.11.002","article-title":"A patient with neuro-Beh\u00e7et's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade","volume":"109","author":"Alty","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0565","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.49.5.725","article-title":"Treatment of intestinal Beh\u00e7et's syndrome with chimeric tumour necrosis factor alpha antibody","volume":"49","author":"Travis","year":"2001","journal-title":"Gut"},{"issue":"29\u201330","key":"10.1016\/j.autrev.2014.01.056_bb0570","first-page":"414","article-title":"Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders","volume":"132","author":"Aeberli","year":"2002","journal-title":"Swiss Med Wkly"},{"issue":"8","key":"10.1016\/j.autrev.2014.01.056_bb0575","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s10067-006-0410-3","article-title":"Successful treatment of life-threatening intestinal ulcer in Beh\u00e7et's disease with infliximab: rapid healing of Beh\u00e7et's ulcer with infliximab","volume":"26","author":"Ju","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2014.01.056_bb0580","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3904\/kjim.2007.22.1.24","article-title":"Remission of intestinal Beh\u00e7et's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab)","volume":"22","author":"Lee","year":"2007","journal-title":"Korean J Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2014.01.056_bb0585","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3109\/s10165-010-0370-y","article-title":"Efficacy of combination therapy of anti-TNF-\u03b1 antibody infliximab and methotrexate in refractory entero-Beh\u00e7et's disease","volume":"21","author":"Iwata","year":"2011","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2014.01.056_bb0590","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/rheumatology\/40.4.473","article-title":"Treatment of recalcitrant orogenital ulceration of Beh\u00e7et's syndrome with infliximab","volume":"40","author":"Robertson","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2014.01.056_bb0595","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/ard.2003.010975","article-title":"Successful treatment of genital ulcers with infliximab in Beh\u00e7et's disease","volume":"63","author":"Haugeberg","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2014.01.056_bb0600","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1365-2133.2005.06914.x","article-title":"Infliximab treatment for severe orogenital ulceration in Beh\u00e7et's disease","volume":"153","author":"Connolly","year":"2005","journal-title":"Br J Dermatol"},{"issue":"4 Suppl. 45","key":"10.1016\/j.autrev.2014.01.056_bb0605","first-page":"S99","article-title":"Infliximab for the treatment of resistant oral ulcers in Beh\u00e7et's disease: a case report and review of the literature","volume":"25","author":"Almoznino","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2014.01.056_bb0610","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/ard.2005.045195","article-title":"Beh\u00e7et's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment","volume":"65","author":"Baki","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.056_bb0615","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.semarthrit.2011.02.006","article-title":"Resolution of Beh\u00e7et's syndrome associated pulmonary arterial aneurysms with infliximab","volume":"41","author":"Schreiber","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"4 Suppl. 67","key":"10.1016\/j.autrev.2014.01.056_bb0620","first-page":"S94","article-title":"Infliximab for life-threatening pulmonary artery aneurysms in Beh\u00e7et's disease. A case report","volume":"29","author":"Tolosa-Vilella","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2014.01.056_bb0625","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/kem103","article-title":"Infliximab in the treatment of hepatic vein thrombosis (Budd\u2013Chiari syndrome) in three patients with Beh\u00e7et's syndrome","volume":"46","author":"Seyahi","year":"2007","journal-title":"Rheumatology (Oxford)"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214000688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214000688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T01:52:42Z","timestamp":1565142762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214000688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":123,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1568997214000688"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.01.056","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biotherapies in Beh\u00e7et's disease","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.01.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}